Phanes Therapeutics Submits IND Application for First-in-Class Claudin18.2/CD47 Bispecific Antibody PT886 in China

December 8,CDEOfficially shown,Phanes SubmissionThe clinical trial application for PT886 has been accepted.

PT886 is a first-in-class bispecific antibody independently developed by Phanes, targeting Claudin18.2 and CD47, for the treatment of pancreatic cancer, as well as gastric cancer and gastroesophageal junction cancer (GEJ).

PT886 can directly kill tumor cells through macrophage phagocytosis (ADCP activity) and natural killer cell cytotoxicity (ADCC activity), and can expand the scope of tumor killing by simultaneously targeting claudin 18.2 and CD47 expressed on the surface of tumor cells.

In addition, PT886 is expected to induce the presentation of tumor neoantigens by guiding tumor cells into phagocytic antigen-presenting cells (APCs), and indirectly activate T cells to kill claudin 18.2-expressing tumor cells by recognizing tumor neoantigens, thereby stimulating the adaptive immune system.

The anti-CD47 arm of PT886, through differentiated design, exhibits minimal binding to human red blood cells while maintaining strong binding activity to CD47 on the surface of tumor cells, thus offering an improved benefit/risk profile compared to other CD47 molecules.

https://mp.weixin.qq.com/s/gUtk3nT23YKzsPAdag_aPg